SARS-CoV-2 Omicron-B.1.1.529 Leads to Widespread Escape from Neutralizing Antibody Responses

On 24 November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.

Citing Articles

More common RNAemia in the early stage of severe SARS-CoV-2 BF.7.14 infections in pediatric patients.

Sun Y, Zhu R, Pan Y, De R, Liu S, Jia L Biosaf Health. 2025; 6(1):5-11.

PMID: 40078310 PMC: 11895017. DOI: 10.1016/j.bsheal.2023.12.002.

Function and structure of broadly neutralizing antibodies against SARS-CoV-2 Omicron variants isolated from prototype strain infected convalescents.

Li D, Hu C, Su J, Du S, Zhang Y, Ni W J Transl Med. 2025; 23(1):212.

PMID: 39985112 PMC: 11844185. DOI: 10.1186/s12967-025-06162-6.

Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.

Yu C, Wang W, Zhang Q, Jin Z Front Immunol. 2025; 16:1510770.

PMID: 39958350 PMC: 11825795. DOI: 10.3389/fimmu.2025.1510770.

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination.

Awadalla M, AlRawi H, Henawi R, Barnawi F, Alkadi H, Alyami A Front Immunol. 2025; 16:1526444.

PMID: 39911379 PMC: 11794813. DOI: 10.3389/fimmu.2025.1526444.

SARS-CoV-2 evolution on a dynamic immune landscape.

Raharinirina N, Gubela N, Bornigen D, Smith M, Oh D, Budt M Nature. 2025; 639(8053):196-204.

PMID: 39880955 PMC: 11882442. DOI: 10.1038/s41586-024-08477-8.

References

Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K . Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-670. PMC: 9531318. DOI: 10.1038/s41586-021-04386-2. View

Dejnirattisai W, Zhou D, Ginn H, Duyvesteyn H, Supasa P, Case J . The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021; 184(8):2183-2200.e22. PMC: 7891125. DOI: 10.1016/j.cell.2021.02.032. View

Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M . Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021; 29(5):819-833.e7. PMC: 7953435. DOI: 10.1016/j.chom.2021.03.005. View

Pettersen E, Goddard T, Huang C, Meng E, Couch G, Croll T . UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2020; 30(1):70-82. PMC: 7737788. DOI: 10.1002/pro.3943. View

Krissinel E, Henrick K . Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007; 372(3):774-97. DOI: 10.1016/j.jmb.2007.05.022. View

Walls A, Tortorici M, Snijder J, Xiong X, Bosch B, Rey F . Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A. 2017; 114(42):11157-11162. PMC: 5651768. DOI: 10.1073/pnas.1708727114. View

Liu C, Ginn H, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A . Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; 184(16):4220-4236.e13. PMC: 8218332. DOI: 10.1016/j.cell.2021.06.020. View

Cohen-Khait R, Schreiber G . Low-stringency selection of TEM1 for BLIP shows interface plasticity and selection for faster binders. Proc Natl Acad Sci U S A. 2016; 113(52):14982-14987. PMC: 5206572. DOI: 10.1073/pnas.1613122113. View

Winter G, Waterman D, Parkhurst J, Brewster A, Gildea R, Gerstel M . DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol. 2018; 74(Pt 2):85-97. PMC: 5947772. DOI: 10.1107/S2059798317017235. View

10.

Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer A, Ginn H . Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184(11):2939-2954.e9. PMC: 8008340. DOI: 10.1016/j.cell.2021.03.055. View

11.

Ke Z, Oton J, Qu K, Cortese M, Zila V, McKeane L . Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 2020; 588(7838):498-502. PMC: 7116492. DOI: 10.1038/s41586-020-2665-2. View

12.

Peleg Y, Unger T . Application of the Restriction-Free (RF) cloning for multicomponents assembly. Methods Mol Biol. 2014; 1116:73-87. DOI: 10.1007/978-1-62703-764-8_6. View

13.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

14.

Yuan M, Liu H, Wu N, Lee C, Zhu X, Zhao F . Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020; 369(6507):1119-1123. PMC: 7402627. DOI: 10.1126/science.abd2321. View

15.

Sun Y, Wang L, Feng R, Wang N, Wang Y, Zhu D . Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms. Cell Res. 2021; 31(5):597-600. PMC: 8005859. DOI: 10.1038/s41422-021-00497-7. View

16.

Caly L, Druce J, Roberts J, Bond K, Tran T, Kostecki R . Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust. 2020; 212(10):459-462. PMC: 7228321. DOI: 10.5694/mja2.50569. View

17.

Zahradnik J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J . SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol. 2021; 6(9):1188-1198. DOI: 10.1038/s41564-021-00954-4. View

18.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

19.

Aricescu A, Lu W, Jones E . A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr. 2006; 62(Pt 10):1243-50. DOI: 10.1107/S0907444906029799. View

20.

Pinto D, Park Y, Beltramello M, Walls A, Tortorici M, Bianchi S . Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815):290-295. DOI: 10.1038/s41586-020-2349-y. View